Jazz Pharmaceuticals (NASDAQ:JAZZ) will report earnings after markets close on Tuesday, May 7th. Jazz Pharmaceuticals, Inc. develops and markets treatments for neurological and psychiatric conditions. The Company produces treatments for cataplexy, excessive daytime sleepiness, and ethylene glycol and methanol poisoning in humans.
Here is your Cheat Sheet to Jazz Pharmaceuticals Earnings:
Earnings Expectations: Analysts expect earnings of $1.35 per share on revenues of $189.92 million. Currently, the company’s P/E ratio stands at 11.93.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.39 to a profit $1.46. For the current year, the average estimate is a profit of $5.87, which is better than the estimate ninety days ago.
Here’s how Jazz Pharmaceuticals has been performing on an annual basis:
|Revenue ($) in millions||67.51||128.45||173.78||272.28||585.98|
|Diluted EPS ($)||-7.19||-0.23||0.83||2.67||4.79|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||83.54||108.41||129.54||175.52||183.70|
|Diluted EPS ($)||0.7896||0.48||0.45||0.55||3.275|
Jazz Pharmaceuticals has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)